ArticleFrontiers in endocrinology2026
Interpretable machine learning for presurgical differentiation of Hürthle cell carcinoma and adenoma: a SHAP-augmented approach.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The preoperative differentiation between benign Hürthle cell adenoma (HCA) and malignant Hürthle cell carcinoma (HCC) remains clinically challenging. This study aimed to develop an interpretable machine learning framework to improve diagnostic accuracy and assist clinical decision-making. Methods: We retrospectively enrolled 554 patients (280 HCA, 274 HCC) from a single center. Fifteen clinical, serological, and ultrasonographic variables were incorporated. Following rigorous feature selection via LASSO and Random Forest algorithms, four advanced machine learning models and logistic regression (LR) were trained and evaluated using 10-fold cross-validation. The SHapley Additive exPlanations (SHAP) and Individual Conditional Expectation (ICE) trajectories were utilized to interpret the optimal model globally and locally. Results: The XGBoost model demonstrated superior discriminative performance, achieving an Area Under the Curve (AUC) of 0.911, significantly outperforming LR (AUC = 0.746). Decision curve analysis confirmed its higher clinical net benefit. SHAP analysis demystified the algorithmic "black box," identifying vascularity grade, absent halo sign, and elevated serum thyroglobulin as top malignant predictors. Furthermore, patient-specific ICE trajectories successfully simulated counterfactual clinical reasoning for misclassified cases. Conclusion: The SHAP-augmented XGBoost framework provides highly accurate, transparent, and personalized presurgical risk stratification for Hürthle cell neoplasms, potentially reducing unnecessary diagnostic thyroidectomies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.